Preclinical and clinical development of neoantigen vaccines

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer neoantigens arise from somatic mutations, making them ideal targets for cancer immunotherapy due to their immunogenicity and tumor-specific expression.
• Advances in next-generation sequencing and computational analysis have enabled the discovery of these crucial neoantigens.
• While checkpoint blockade therapy utilizes neoantigens, neoantigen vaccines are under investigation in preclinical and early-phase human trials.

Purpose of the Study:

• To evaluate the safety and efficacy of neoantigen vaccines in cancer immunotherapy.
• To assess the T-cell responses induced by different types of neoantigen vaccines.
• To explore the potential of combining neoantigen vaccines with other immunotherapies.

Main Methods:

• Utilizing next-generation sequencing and computational analysis for neoantigen discovery.
• Developing and testing various neoantigen vaccine platforms, including dendritic cell, synthetic long peptide, and RNA-based vaccines.
• Conducting preclinical studies and early-phase human clinical trials.

Main Results:

• Preliminary clinical trial results indicate that dendritic cell, synthetic long peptide, and RNA-based neoantigen vaccines are safe.
• These vaccines effectively induce both CD8+ and CD4+ neoantigen-specific T-cell responses.
• Ongoing trials are investigating neoantigen vaccines in melanoma, breast cancer, and non-small-cell lung cancer.

Conclusions:

• Neoantigen vaccines represent a promising avenue in cancer immunotherapy, demonstrating safety and immunogenicity.
• Combination therapies, particularly with checkpoint blockade, are crucial for overcoming immune escape mechanisms in cancer.
• Further research is warranted to optimize neoantigen vaccine strategies and their integration into clinical practice for diverse cancer types.